Truist Securities Reiterates Buy Rating on Evolent Health (EVH)
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Piper Sandler Reiterates Overweight Rating on Evolent Health (EVH)
August 22, 2024 3:59 PM EDTPiper Sandler analyst Jessica Tassan reiterated an Overweight rating and $38.00 price target on Evolent Health (NYSE: EVH).
The analyst comments "Reuters reports that EVH is weighing sale, following takeover interest. The publication states that EVH has received initial offers and that potential acquirers could include PE firms or ELV (not covered) in combination with a PE partner. Our thoughts on today's news. 1. EVH is defining and dominating the market for value-based specialty care management. This is a $732B TAM which we define our white paper on the space here. 2. EVH has assembled best-in-class... More
BTIG Reiterates Buy Rating on Evolent Health (EVH)
August 22, 2024 3:57 PM EDTBTIG analyst David Larsen reiterated a Buy rating and $45.00 price target on Evolent Health (NYSE: EVH)
The analyst comments "Shares of EVH are trading up due to an article in Reuters, stating that several private equity firms, and at least one large health plan, are in discussions to potentially acquire EVH. The press report highlights that a process started after EVH received in-bound... More
RBC Capital Reiterates Outperform Rating on Evolent Health (EVH), discusses M&A chatter
August 22, 2024 3:39 PM EDTRBC Capital analyst Sean Dodge reiterated an Outperform rating and $42.00 price target on Evolent Health (NYSE: EVH).
The analyst said: "There has been a lot of M&A/consolidation over the last 24-months in the value-based care (VBC) space and in our opinion EVH is the best (and most attractively-valued) of the... More
Exclusive-Evolent Health in sale talks after receiving takeover interest, sources say
August 22, 2024 2:44 PM EDTBy Milana Vinn and Anirban Sen
NEW YORK (Reuters) -Evolent Health is in talks with private equity firms and healthcare services providers for a potential sale, in a process that kicked off after it received takeover interest, people familiar with the matter said on Thursday.
Private equity firms TPG, CD&R and KKR are among the parties that have expressed interest in a deal for healthcare software provider Evolent, which has a market value of about $3.8 billion, the sources said. TPG was one of the early investors in Evolent.
Health insurer Elevance Health is also... More
Evolent Health in talks on sale after attracting interest: Reuters
August 22, 2024 2:43 PM EDTInvesting.com -- Evolent Health, a healthcare services provider with a market value of $3.3 billion, is in talks with private equity firms and other companies for a potential sale, Reuters reported Thursday, citing people familiar with the matter.
Private equity firms TPG, CD&R and KKR are among... More
Evolent Health (EVH) October 27.50 and 32.50 calls active after Reuters says in sale talks
August 22, 2024 2:12 PM EDTEvolent Health (NYSE: EVH) 30-day option implied volatility is at 48; compared to its 52-week range of 30 to 103 after Reuters says in sale talks. Call put ratio 2.4 calls to 1 put with focus on October 27.50 and 32.50 calls.
... MoreEvolent Health (EVH) In Sale Talks After Inbound Interest - Reuters
August 22, 2024 1:21 PM EDTEvolent Health In Sale Talks After Inbound Interest- Reuters
... More
